Comparison · NCT00605865-513ad332
Inpatient vs Outpatient: Factors Considered to Affect the Efficacy of Sertraline: Outpatient/Inpatient
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Inpatient vs Outpatient: Factors Considered to Affect the Efficacy of Sertraline: Outpatient/Inpatient. Trial comparisons, record NCT00605865-513ad332. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00605865-513ad332
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.78 | 0.7 | 0.843 | wilson | |
| Risk in group 2 | 0.861 | 0.843 | 0.877 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0813 | -0.163 | -0.0156 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.906 | 0.824 | 0.995 | log | |
| Odds ratio, group 1 over group 2 | 0.572 | 0.367 | 0.89 | log | |
| Number needed to treat, for one fewer participant with the outcome on Inpatient than on Outpatient | 12.3 | 6.15 | 64.2 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Inpatient | Participants as inpatients who took Sertraline according to Japanese Package Insert | 99 | 127 | OG000 |
| Group 2 | Outpatient | Participants as outpatients who took Sertraline according to Japanese Package Insert | 1,410 | 1,638 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Factors Considered to Affect the Efficacy of Sertraline: Outpatient/Inpatient
- Description
- Number of participants with responders of Sertraline to determine whether outpatient or inpatient is significant factor
- Time frame
- Baseline up to 16 weeks
- Population
- The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).
Source ClinicalTrials.gov
Trial
- Title
- Drug Use Investigation of Jzoloft.
- NCT number
- NCT00605865
- Phases
- Conditions
- Panic Disorder, Depression
- Interventions
- Sertraline hydrochloride
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Results first posted
- 2012-10-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00605865?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00605865-513ad332